A combination of metabolic disorders manifested by increased blood glucose levels causes Diabetes mellitus. Patients with diabetes are more prone to morbidity and increased rate of mortality compared to the general population, with a substantial contribution to healthcare costs. One of the significant risk factors for cardiovascular problems is Diabetes Mellitus. Hence, the additional cardiovascular beneficial effect has been reported in various new antidiabetic agents, including DPP-4 inhibitors. This literature aims to evaluate the cardiovascular efficacy and safety of DPP-4 inhibitors. We used PubMed search engine to search for relevant studies. We used different Mesh words, including "DPP-4, Diabetes mellitus, cardiovascular risk, heart failure". DPP-4 inhibitors may provide cardiovascular benefit amount type-2 diabetic patients. There is still debate about the increased risk of heart failure hospitalization. Generally, DPP-4 inhibitors are secure, and endure and accepted by the patients. It should be noted that a beneficial atherosclerotic effect was reported with inhibitors of DPP-4. However, the HF hospitalization risk remains an area of debate. Further multi-national trials are recommended to establish DPP-4 inhibitors' cardiovascular efficacy safety.
1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40-50. doi:10.1016/j.diabres.2017.03.024
2. Glovaci D, Fan W, Wong ND. Epidemiology of Diabetes Mellitus and Cardiovascular Disease. Curr Cardiol Rep. 2019;21(4):21. doi:10.1007/s11886-019-1107-y
3. Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25-32. doi:10.1177/2047487319878371
4. Luo Y, Lu K, Liu G, Wang J, Laurent I, Zhou X. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Drug Investig. 2018;38(12):1089-108.
5. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(S2):S14-21.
6. Fei Y, Tsoi MF, Kumana CR, Cheung TT, Cheung BMY. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. Int J Cardiol. 2018;254:291-6. doi:10.1016/j.ijcard.2017.12.039
7. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23(4):479-86. doi:10.1016/j.beem.2009.03.004
8. Gadsby R. New treatments for type 2 diabetes--the DPP4 inhibitors. Prim Care Diabetes. 2007;1(4):209-11. doi:10.1016/j.pcd.2007.10.004
9. Lambeir AM, Scharpé S, De Meester I. DPP4 inhibitors for diabetes--what next? Biochem Pharmacol. 2008;76(12):1637-43. doi:10.1016/j.bcp.2008.07.029
10. Xia C, Goud A, D’Souza J, Dahagam C, Rao X, Rajagopalan S, et al. DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Fail Rev. 2017;22(3):299-304. doi:10.1007/s10741-017-9617-4
11. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes. JAMA. 2018;319(15):1580. doi:10.1001/jama.2018.3024
12. Papagianni M, Tziomalos K. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. Hippokratia. 2015;19(3):195-9.
13. Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circ Res. 2018;122(10):1439-59.
14. Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019;18(1):1-3. doi:10.1186/s12933-019-0916-z
15. Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus. Circ Heart Fail. 2017;10(9):e003957.
16. Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, et al. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Prim Care Diabetes. 2019;13(3):204-11. doi:10.1016/j.pcd.2019.01.003
17. Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, et al. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovasc Diabetol. 2020;19(1):1-11.
18. Dawwas GK, Smith SM, Park H. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists. Cardiovasc Diabetol. 2018;17(1):1-9. doi:10.1186/s12933-018-0746-4
19. Liu H, Guo L, Xing J, Li P, Sang H, Hu X, et al. The protective role of DPP4 inhibitors in atherosclerosis. Eur J Pharmacol. 2020;875:173037. doi:10.1016/j.ejphar.2020.173037
20. Lee S, Lee SA, Choi B, Kim YJ, Oh SJ, Choi HM, et al. Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis. Heart. 2020;106(23):1824-31.
21. Nishida S, Matsumura T, Senokuchi T, Murakami-Nishida S, Ishii N, Morita Y, et al. Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions. Biochem Biophys Res Commun. 2020;524(1):8-15. doi:10.1016/j.bbrc.2020.01.027
Copyright © 2024 - All Rights Reserved - Archives of Pharmacy Practice
Developed by Archives of Pharmacy Practice
